Why the study?
Do Mitogen-Activated Protein Kinase Inhibitors improve heart function and prevent fibrosis in cardiomyopathy caused by LMNA mutations?
Do Mitogen-Activated Protein Kinase Inhibitors improve heart function and prevent fibrosis in cardiomyopathy caused by LMNA mutations?
ERK and JNK signaling inhibitors show potential for treating cardiomyopathy caused by LMNA mutations by improving heart function and preventing fibrosis.
Should not change practice in LMNA cardiomyopathy; leaves open translation of ERK/JNK inhibition to human trials.
Inhibitors of ERK and JNK signaling could potentially be used to treat humans with cardiomyopathy caused by LMNA mutations.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: